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ABBREVIATIONS AND ACRONYMS 
 
 
[Ca
2+
]i: intracellular Ca
2+ 
[Ca
2+
]iD : diastolic Ca
2+  
level 
AP: action potential 
APD: action potential duration 
ATP: adenosine-triphosphate 
ATX-II: anemone toxin 
cAMP: cyclic adenosine-monophosphate 
CDI: Ca
2+ 
dependent inactivation 
CICR: Ca
2+
 induced Ca
2+
 release 
CN
-
: cyanate 
DAD: delay after depolarization 
EAD: early after depolarization 
ECC: excitation-contraction coupling 
ICaL: L-type Ca
2+
 current 
ICa : inward Ca
2+
 current  
INaL: Late sodium current 
LQTS1,2,3: long QT syndromes  
NBC: Na+- HCO3
-
 cotransporter 
NCX: Na
+
- Ca
2+
 exchanger 
NHE: Na
+
/H
+
 exchanger  
NKA : Na
+
/K
+
 ATPase 
ORM-10103 : NCX inhibitor 
PKA: protein kinase A  
PLB: phospholamban 
PMCA : sarcolemmal Ca
2+
 ATPase 
ROI : region of interest 
ROS : reactive oxigen species 
RT50: half relaxation time 
RyR: ryanodine receptor 
SERCA: sarcoplasmic reticulum Ca
2+
 ATPase 
SR: sarcoplasmic reticulum 
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SUMMARY 
 
Cardiovascular diseases are the leading cause of mortality for both men and women 
worldwide. In many of the cardiac diseases [Ca
2+
]i overload is a crucial factor in initiation 
and progression of the malignant intracellular perturbations leading to cell death. A 
substantial rise in cellular Na
+
 content is often the primary initiator of the [Ca
2+
]i overload, 
leading to arrhythmogenesis. This pathomechanism is also characteristic of ischemia (and 
especially reperfusion) or arrhythmia types with genetic origin (e.g. LQT3 syndrome). 
Indeed, [Ca
2+
]i overload induced arrhythmias are among the most common cardiac 
diseases. 
By its regulatory effect on the cytoplasmic Ca
2+ 
the Na
+
/Ca
2+
 exchanger (NCX) has a 
crucial role in the ionic homeostasis of the heart. In physiological conditions its major role 
is to remove the excess Ca
2+
, and to stabilize the cellular Ca
2+
 content and the magnitude 
and kinetics of the [Ca
2+
]i transient. Excessive increase in the inward Na
+
 current may lead 
to arrhythmogenesis either via [Na
+
]i induced [Ca
2+
]i overload or by significantly 
prolonging the duration of the action potential (APD).  
The primary aim of the present project was to investigate in detail the effects of [Ca
2+
]i 
overload, induced either by increased late Na
+
 current or by acute ischemia/reperfusion, on 
characteristic variables of the [Ca
2+
]i transient (CaT) and action potential (AP), in isolated 
canine cardiomyocytes.  
In order to meet our goals we first developed a simulated ischemia/reperfusion model 
to be used at the cellular level. (There was minimal related information in the literature.) 
Next, we applied this model to canine cardiomyocytes and investigated the variables of the 
APs and CaTs recorded from the cells in several experimental states. When applying the 
protocol “per se”, ischemia/reperfusion induced changes were relatively moderate, 
therefore this protocol seems to be appropriate to evaluate the effects of moderate 
ischemia. In order to model more severe ischemia, the sarcolemmal Na
+
/K
+
 ATPase was 
blocked simultaneously. Compared to the low-flow protocol, the observed changes in 
[Na
+
]i and [Ca
2+
]i homeostasis in strophantidine treated cells were much more dramatic 
during both ischemia and reperfusion. 
On the whole, tha major results demonstrate that selective NCX inhibition exhibits 
considerable protection against the arrhythmogenic effect and cell death due to [Ca
2+
]i 
overload when induced by increased late sodium current and ischemia/reperfusion. 
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1.INTRODUCTION 
1.1.  Intracellular Ca2+ and Na+ homeostasis  
1.1.1. Intracellular Ca2+ handling in cardiac myocytes 
Intracellular Ca
2+
 cycling (see Fig.1.) in the cardiomyocytes is a result of the tightly 
regulated Ca-influx and efflux pathways. The membrane depolarization initiates the 
sarcolemmal Ca
2+
 influx through the L-type Ca
2+
 channels, which are located in the 
membrane of T-tubules near the junctional region of the sarcoplasmic reticulum (SR) [1-
2]. This “trigger calcium” is thought to directly activate the calcium release channels 
embedded in the junctional SR. Opening of these calcium-sensitive Ca
2+
 release channels 
(ryanodine receptors, RyR) partially empties the internal store of calcium. This mechanism 
is known as calcium-induced Ca
2+
 release (CICR) [3].  
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Fig.1.: Ion channels, and transporters contributing in intracellular Ca
2+
 and Na
+ 
movements in cardiomyocytes. In the right part of the figure the optically measured [Ca
2+
]i 
transient (Ca
2+
 release from the SR) is depicted. Detailed description can be found in 
section 1.1.1 and 1.1.2. (Modified from Bers [4.].)  
Binding of calcium to troponin C in the contractile apparatus initiates muscle 
contraction (systole). Reuptake of calcium into the sarcoplasmic reticulum by the 
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phospholamban-regulated sarcoplasmic reticulum Ca
2+
-ATPase (SERCA) allows for 
cardiac relaxation (diastole). β receptor–mediated protein kinase A (PKA) stimulation 
regulates this Ca
2+
 cycling by phosphorylating L-type Ca
2+
 channels, RyR, and 
phospholamban. In normal hearts, sympathetic stimulation activates β1-adrenergic 
receptor, which in turn stimulates the production of cAMP and thereby activates PKA. 
PKA phosphorylates phospholamban and RyR, both of which contribute to an increased 
intracellular [Ca
2+
]i transient [4-5]. Beside to these channels, NCX plays an essential role in 
removal of Ca
2+
, also contributes to the Ca
2+
 trigger. The cardiac contractility and force 
development depend on the free intracellular Ca
2+
 level and the Ca
2+
 sensitivity of the 
cardiomyocytes. SERCA and the NCX play key roles in maintaining the balance of the 
cellular Ca
2+ 
homeostasis. Importantly, the role of NCX can profoundly increase in 
pathological circumstances, which may result in cellular Ca imbalance. Any major and 
chronic imbalance in Ca
2+
 handling, exceeding the physiological shifts in [Ca
2+
]i, may 
result in gradual cellular [Ca
2+
]i overload, leading to highly increased arrhythmia 
propensity, or cell injury. 
1.1.2. Regulation of intracellular Na+  
In steady-state conditions intracellular Na
+ 
is determined by the balance between 
Na
+ 
influx and efflux. There are four major pathways for Na
+ 
influx: 1. Voltage-gate Na
+
 
channels, 2. Na
+
/H
+
 exchange (NHE), 3. Na
+
- HCO3
-
 cotransporter (NBC), 4. Na
+
/Ca
2+
 
exchange. Intracellular Na
+
 concentration and Na
+
 pump activity belong to the most 
important factors of the NCX regulation. Indeed, in experimental models of heart diseases 
associated with increased internal Na level (for example in ischemia/reperfusion injury), 
activity of NCX can be significantly elevated, which can contribute to the cellular the 
[Ca
2+
]i overload. Moreover, intracellular Na
+
 plays an important role in regulating the pH 
via the Na
+
/H
+
 exchange and Na
+
- HCO3- cotransporter [5]. 
The sarcolemmal Na
+
/K
+
 ATP-ase activity is essential for the Na
+
 gradient that 
drives ion transport processes critical for normal cardiac function. This pump transports 3 
Na
+
 and 2 K
+
 against their electromechanical gradients for each ATP hydrolysed, 
maintaining the low intracellular Na
+
 level and the high K
+
 level. That is the reason why 
the Na
+
/K
+
 ATP-ase is very important in the cardiac myocytes. The transsarcolemmal Na
+
 
gradient established by the Na
+
 pump activity is important for AP depolarization and 
regulation of NCX. More detailed studies revealed that the Na
+
 efflux through the pump 
maintains the low subsarcolemmal Na
+
 level, establishing a functional interaction between 
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the Na
+
/K
+
 ATP-ase and the NCX activity Fig.1. The rise in [Na
+
]i occurs in the face of 
greater Na
+
 influx due to more frequent and larger Na
+
 current and enhanced Na
+
 entry via 
NCX which has to extrude more Ca
2+
 to balance the larger Ca
2+
 entry via L-type Ca
2+
 
channels. Enhanced Na
+
 influx could also raise [Na
+
]i, and this explains the higher [Na
+
]i 
in ventricular myocytes. Na
+
 influx through the pump may also have changes in NCX 
activity, because the pump may functionally interact with NCX [6]. Alteration in 
intracellular Na
+ 
concentration during diastole and higher intracellular Na
+
 concentration in 
cardiomyocytes can activate the reverse mode of NCX and causes an elevated intracellular 
Ca
2+ 
concentration which can result in the [Ca
2+
]i overload and cardiac injury. Thus, 
intracellular  Na
+
 plays an important role in the intracellular Ca balance  and presents an  
important factor in the excitation-contraction coupling (ECC). 
Moreover the late Na
+
 current (INaL) influences the cardiac action potential 
repolarization, participates in Na
+
 and Ca
2+
 homeostasis of cardiac cells, and can promote 
arrhythmogenic activities [7-8]. Upregulation of INaL increases intracellular Na
+
 
concentration which causes in the SR the [Ca
2+
]i overload. SR [Ca
2+
]i overload then causes 
spontaneous Ca
2+
 release from SR which drives forward mode of NCX to depolarize the 
membrane. Furthermore the plateau phase of the AP has an important role in maintaining 
the INaL. 
1.2. Regulation of the NCX by intracellular Ca
2+
 and Na
+
 concentrations 
 
The primarily role of the NCX is to pump Ca
2+
 out of cell using Na
+
 concentration 
gradient across the cell membrane. The driving force of NCX determines the kinetics of 
the NCX during an action potential governed by the [Na
+
] and [Ca2
+
] levels (both 
intracellular and extracellular) and actual membrane potential (Fig.2). During the rapid 
upstroke of AP, when the [Ca2
+
]i is low, but the membran is depolarized, the NCX operates 
in its reverse mode, causing Ca
2+
 influx. When Ca
2+
 releases form the SR, the high [Ca
2+
]i 
turns the NCX kinetics in forward mode to extrude [Ca2
+
]i [9]. 
Under pathological conditions, the [Na
+
]i can be markedly increased causing 
considerable shift in the driving force of the NCX thus the Ca
2+
 influx via reverse mode 
can lead to the [Ca
2+
]i overload and arrhythmogenic diastolic releases.  
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INCX
 
Fig.2.: Schematic presentation of INCX  during AP. Normal ventricular action potential and the 
corresponding NCX current are shown in the upper and lower part of the figure, respecively. The 
outward current (= reverse mode NCX transport) is only present in the early phase of the AP. INCX 
is an inward curren (= forward mode NCX transport) during most of the the AP. 
 
Outward NCX current is present only in the very early phase of the AP, and during 
the ventricular AP the NCX current is mostly an inward current, which reflects the Ca 
extrusion via NCX. Thus, NCX works almost exclusively in the Ca
2+
 extrusion mode, 
driven mostly by the high subsarcolemmal [Ca
2+
]i transient. The driving force of NCX 
depends on Na
+
 and Ca
2+
 concentrations at either side of the plasma membrane. 
Furthermore, the actual value of the membrane potential is also critical in determinig the 
direction of the NCX operation, with positive potential at the beginning of the AP favoring 
the reverse mode. In contrast, negative membrane potential at the end of the AP favours 
the forward mode activity. NCX is electrogenic and carries inward (depolarizing) current 
in forward mode and outward (repolarizing) current in reverse mode [9]. 
Molecular structure of NCX : NCX consist of three isoforms of a multigene family, 
NCX1, NCX2, NCX3. These isoforms have a very similar molecular structure. NCX1 is a 
110kDa (Fig.3) protein expressed particularly in cardiac muscle and brain. NCX2 and 
NCX3 are expressed in other tissues. Although recent research revealed many details of the 
NCX structure its exact operation is still not completely understood [10] 
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Fig.3.: The schematic molecular structure of NCX. The molecule contains four 
transmembrane segments, a P-loop domain, and the second α repeat (α-2). The central 
regions of the two α repeats facing opposite in the membrane and contain amino acids that 
are essential for normal NCX function. The two CBD domains are different (CBD1, 
CBD2). CBD1 binds four Ca
2+
 ions with high affinity [11] and Ca
2+
 binding is thought to 
be followed by a major conformational change responsible probably for the regulatory 
action of Ca
2+
 on NCX. CBD2 contains the variable alternative splicing region, as an 
essential structural unit [12]. 
 
1.2. Cardiac action potential  
 
The cardiac action potential represents the time course of the cardiac 
transmembrane potential, and it is a key determinant of the cardiac electrical activity, 
which is shaped by several ionic currents and transporters (Fig.4) 
The cardiac AP is consisted of four different phases: 
 Phase 0 : Rapid Depolarization 
Once a stimulus is delivered to excitable cells, this evokes an action potential that is 
characterized by an abrupt change in voltage leading to "depolarization" of these cells due 
to opening of the fast Na
+
 channels. The upstroke of the cardiac action potential is due to 
the sudden increase in conductance of the membrane to Na
+
, mediated by opening of the 
fast, voltage gated Na channels.  
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 Phase 1 : Early Rapid Repolarization 
The membrane repolarizes quickly and transiently to nearly 0 mV due to the inactivation of 
the sodium current, INa, and the activation of the  transient outward K
+
 current (Ito). This 
current is rapidly activated by the depolarized membrane voltage and increases 
conductance to K
+
 along its electrochemical gradient. The Ca
2+ 
activated chloride current, 
ICl,Ca, also contributes to the total outward current during Phase 1, promoting the early 
repolarization. Furthermore, the Na
+
/Ca
2+
 exchanger operating in reverse mode,  also 
produces an outward Na
+
 current during this phase [13]. 
 Phase 2 : Plateau Phase 
In this phase the plateau voltage is maintained by the balance between the outward (K
+
 and 
Cl
-
 currents) and inward currents. The major components of the latter are the Ca
2+
 current 
via the L-type Ca
2+
 channel and Na
+ 
current via the NCX forward mode operation. In 
Phase 2, K
+
 conductance reaches almost a standstill despite the large electrochemical 
gradient for K
+
 ions at this plateau voltage [14-15]. 
 Phase 3 : Final Rapid Repolarization 
During this final phase of the action potential before cells return back to the resting 
membrane potential, repolarization occurs rapidly via two currents: a time-dependent 
inactivation of the L-type Ca
2+
 channel, ICaL, and activation of the repolarizing K
+
 currents, 
the slow and rapid delayed rectifiers, IKs and IKr, and the inwardly rectifying K
+
 currents, 
IK1. This results in an increase in the movement of positive ions out of the cell and a return 
to the resting membrane potential seen in Phase 4 of the action potential. In atrial 
myocytes, the acetil-cholin sensitive K
+
 current, IKAch, and the ultra-rapid atrial delayed 
rectifier K
+
 current, IKur are also important contributors of the repolarization phase.  These 
latter currents are investigated as potential targets for novel atrial-selective antiarrhythmic 
agents.  
 Phase 4 : Resting Membrane Potential 
The intracellular space of resting cardiac myocytes is 70-80 millivolts (mV) more negative 
relative to the outside of the cell due to the distribution of the cations Na
+
, K
+
 and Ca
2+
. In 
addition, there is an abundance of open K
+
 channels at rest, thus the resting membrane 
potential approximates the equilibrium potential of K
+ 
[16]. Potassium outward current 
(keeping the inside of the cell negative) through open, inwardly rectifying K
+
 channels, IK1, 
primarily determines the resting membrane potential in atrial, ventricular and Purkinje cells 
[17]. 
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Fig.4.: The phases of the cardiac action potential and the underlying ion currents during a 
representative ventricular action potential.. The transmembrane ion currents are shown in 
the lower panel. The inward currents are depicted as downward deflections. Note that the 
amplitudes of the currents are not proportional with each other. The ions responsible for 
the currents are marked at left side of the lower panel (modified from Ravens et al [18]) 
 
1.4. Interaction between Ca
2+
 homeostasis and AP  
 
The cardiac AP, and consequently some related ion currents, are highly sensitive to 
shifts in extra- and/or intracellular Ca
2+
 levels. The L-type channel is the major pathway 
for calcium entry into the cell thus in addition to the initiation of the Ca
2+
 cycle its 
contribution to the maintaining of the plateau phase of the AP is significant. The most 
important connection between the Ca
2+
 cycle and the AP is the Ca
2+
 dependent inactivation 
(CDI) which is mediated by calcium binding to calmodulin (CaM) molecules. CDI could 
be a mechanism for the self-regulation of Ca
2+
 homeostasis via controlling the activity of 
the ICaL.  When [Ca
2+
]i is high, the CDI decreases ICaL by facilitating its inactivation. 
Therefore the actual amount of the released Ca
2+
 directly modulates the Ca
2+
 influx 
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through L-type Ca
2+
 channel. Consequently, this negative feed-back control is crucial in 
the maintenance of the beat-to-beat intracellular Ca
2+
 balance.  
Further Ca
2+
 sensitive currents can also modulate the AP waveform: The delayed 
rectifier K
+
 current (IK) is considered to be one of the most important transmembrane ionic 
currents in ventricular muscle. IK consists of two components, IKr (rapid) and IKs (slow). IKs 
has important role during normal action potential repolarization. The Ca
2+
-activated 
chloride current, ICl(Ca) can serve as a valuable indicator of local [Ca
2+
]i, promoting 
repolarization during Phase 1. The Ca
2+ 
dependent K
+
 channels IK(Ca) play important role in 
a number of processes, involving Ca
2+
-dependent signaling during the AP [18]. 
1.5. Effect of ischemia/reperfusion in cardiomyocytes  
 
Myocardial ischemia has a major consequence: it is acidosis and this contributes to 
the ischemic decline in force, in large part for decreased myofilament Ca
2+
 sensitivity. 
[Ca
2+
]i transient amplitude can be initially decreased. Ischemia can also increase diastolic 
[Ca
2+
]i.  Low intracellular pH stimulates proton extrusion via NHE (and NBC), that is the 
reason why Na
+ 
influx is increased. Furthermore, the Na
+
/K
+
 pump is partially inhibited at 
low pH. These factors lead to the slow recovery of contractility via shift in NCX and 
increase in [Ca
2+
]i and could also lead to [Ca
2+
]i  overload and arrhythmias. [Ca
2+
]i  
overload can lead to cell necrosis during the reperfusion period. Increase in [Ca
2+
]i  and 
oxidative stress-induced dysfunction of sarcoplasmic reticulum are the reasons for cell 
damage during reperfusion. These also contribute to the pathogenesis of 
ischemia/reperfusion induced injury. During ischemia the major way of Ca
2+
 entry is 
reverse mode NCX, due to sarcolemmal depolarization and increased intracellular Na
+
 
concentration. In fact, decreased ATP phosphorylation potential blocks the activity of the 
sarcolemmal Na
+
/K
+
 ATPase, the intracellular Na
+
 concentration rises and the sarcolemma 
is being depolarized. Cytosolic [Na
+
] overload is accentuated by intracellular acidosis, 
which induces Na
+
 entry through the NHE. The ischemia associated acidosis contributes to 
increase cytosolic Ca
2+
 induced by the NHE, which is strongly coupled to NCX, so that in 
long term the cytosolic H
+
 is exchanged with extracellular Ca
2+
 [23-24]. Inhibitors of the 
Na
+
/H
+
 exchanger were found to be protective if used before ischemia, while their 
effectiveness was reduced when given during the reperfusion phase [25-26].  
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1.6. The future perspectives of NCX modulation 
 
Since pharmacological inhibition of the NCX exchanger proved to be beneficial in 
experimental models of cardiac disorders [27], selective NCX inhibitors may represent a 
novel group for the treatment of cardiac diseases. For example, intracellular accumulation 
of Na
+
 in the myocardium during ischemia/reperfusion favors the reverse mode operation 
of NCX, which may contribute to the intracellular accumulation of Ca
2+
 leading to cell 
damage and death [28-29]. Therefore, pharmacological inhibition of NCX by ORM -10103 
may provide cardioprotection by restricting excessive Ca
2+
 accumulation via inhibition of 
the reverse mode operation of NCX [30]. 
Prolongation of the QT interval is a severe risk factor in a number of cardiovascular 
diseases. Two of the genes responsible for long QT syndrome (LQTS), have been 
identified as KCNH2 (LQT2) and SCN5A (LQT3) [31.]. ATX-II is an inhibitor of sodium-
channel inactivation that thereby mimics LQT3, in which a mutation in SCN5A leads to a 
small, persistent component of the inward, depolarizing ion current (INa) via continuous 
reopening of the sodium channel. INa is responsible for rapid initial action potential 
depolarization. Furthermore abnormalities in INa inactivation produce large inward Na
+
 
currents during the cardiac action potential plateau, causing arrhythmias [32]. Against 
increased INaL induced pathologic alterations in [Ca
2+
]i homeostasis selective NCX 
inhibition by ORM-10103 could be highly protective. 
The major problem, however, with the currently available NCX inhibitors is the 
lack of their selectivity. Concomitant inhibition of the L-type Ca
2+
 current is the most 
important limitation of their use in experimental studies. Although combined block of ICaL 
and INCX can also be useful in certain clinical settings, it makes difficult to interpret the 
beneficial effects of the pure NCX inhibition. Therefore, experimental use of the newly 
developed, selective NCX inhibitors is a major advancement in the field of the NCX 
research. 
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1.7. Aims of the study 
 
 The principal aim of the study was to directly study how partial inhibition of the 
Na
+
/Ca
2+
 exchanger via the novel, selective pharmacological agent ORM-10103 influences 
the elements of Ca handling in cardiac cells. Our results describe the effect of the 
application ORM -10103 in dog ventricular cells under increased intracellular Ca
2+
 level.  
 
    The aims of this study were:   
 
 
 To investigate the protective effect of a novel, selective NCX inhibitor ORM-10103 
against the adverse effects of pharmacologically induced Na
+
-induced Ca
2+
 load. 
 To establish a cellular level ischemia/reperfusion injury model (moderate and 
severe ischemia), in which we can characterize the survival rate of the cells, as well 
as the major electrophysiological parameters of AP and CaT.  
 To estimate the potential therapeutic possibilities of selective NCX inhibition 
against adverse effects of ischemia reperfusion injury, applying ORM-10103. 
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2. MATERIALS AND METHODS 
 
 
All animal experiments were carried out in compliance with the Guide for the Care 
and Use of Laboratory Animals (USA NIH publication NO 86-23, revised 1996) and 
conformed to Directive 2010/63/EU of the European Parliament. Furthermore, all 
experimental protocols were approved by the Ethical Committee for Protection of Animals 
in Research of the University of Szeged, Hungary (permit No. I-74-9/2009).  
2.1. Isolation of canine left ventricular cardiomyocytes 
 
Canine ventricular cardiomyocytes were isolated from adult mongrel dogs of either 
sex weighing 10 to 20 kg. Following sedation (xylazine, 1 mg/kg, i.v.) the animals were 
anaesthetized with 30 mg/kg thiopental and anticoagulated with sodium-heparin. The 
proper depth of anesthesia was carefully tested with pupil and pain reflexes. After right 
lateral thoracotomy the heart was quickly removed and immediately rinsed in oxygenated 
modified Locke's solution containing (in mM): Na
+
 140, K
+
 4, Ca
2+
 1.0, Mg
2+
 1, Cl- 126, 
HCO3- 25 and glucose 11. The pH of the solution, bubbled with 95% O2 and 5% CO2 at 
37°C, ranged from 7.35 to 7.45. Excised left ventricular segments were perfused at 37°C 
through the anterior descending coronary artery using a gravity flow Langendorff 
apparatus. First, to remove the blood the heart was washed for 5 min with isolation 
solution containing 1 mM Ca
2+
, than the perfusate was switched to a Ca
2+
-free solution 
containing (in mM) 135 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 10 HEPES, 10 glucose, 
20 taurine, 4.4 NaHCO3, and 5 Na-Pyruvate (pH 7.2 with NaOH). 10 min later, 75 μM 
CaCl2 and 150 U/ml collagenase (Worthington Type II), and 15 min later 0.35 U/ml 
protease (Sigma Type XIV) was added to the perfusate. Cell dissociation lasted for 30-40 
min. At the end of this isolation process the tissue was minced and gently agitated. The 
myocytes were harvested and stored in the isolation solution containing 1 mM Ca
2+
 at 
room temperature for the same day or at 4 °C for next day recordings. Following 
restoration of the external [Ca
2+
] at least 60% of the cardiomyocytes were rod-shaped 
showing clear striation. During measurements the cells were perfused with Tyrode 
solution. The Tyrode solution contained (in mM): 144 NaCl, 0.4 NaH2PO4, 4 KCl, 0.53 
MgSO4, 1.8 CaCl2, 5.5 glucose and 5 HEPES. The pH was set to 7.4 with NaOH. All 
measurements were performed at 37 °C. 
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2.2. Determination of cell viability 
 
Freshly isolated, unloaded cardiomyocytes, subjected to the ischemia/reperfusion 
protocol were visually assessed, classified and counted in randomly selected microscopic 
fields (Olympus IX 71 inverted fluorescence microscope; 20x objective). A representative, 
circular region of the microscopic field (region of interest; ROI), containing predominantly 
contracting cells, was used for analysis. Still images of the ROI were periodically captured 
by an Olympus digital photo camera (C-7070). In order to safely distinguish living and 
dead cells, instead of using vital dyes, we followed another, similarly effective 
classification, utilizing characteristic morphological variables, i.e. the shape and visibility 
of striation of the cells. These data principally differ from those shown in all other figures. 
The reason is that other figures only contain data determined in surviving cells, i.e. all 
those cells survived the full ischemia/reperfusion protocol. However, usually a substantial 
fraction of cells, especially in the nontreated groups did not survive the protocol and their 
incomplete datasets were not considered for statistical analysis. Instead of using vital dyes, 
we followed a similarly effective classification, based simply on the shape and visibility of 
the striation of the cell [29]. This form of classification may also have some benefits since 
with proper experience one is able to reliably dissect crippled, dying cardiomyocytes from 
safely surviving cells. Cardiomyocytes in the ROI were divided into two classes: Class A: 
cells with normal (not significantly shortened) shape, intact border and visible striation; 
Class B: cells dead or at the verge of death, in severe contracture, parallel striation cannot 
be observed. The cells were stimulated (1 Hz) throughout the experiment. The number of 
surviving and dead cells was determined several times (at 0,1.5
th
,3
rd
, 4
 th
,10
 th
,15
 th
,23
 th
,24
 
th
,26
 th
,30
 th
,32
nd
 minutes) during the ischemia/reperfusion protocol. 
2.3. Validation of the simulated ischemia via NADH measurements  
 
Parallel to the shift from aerobic to anaerobic metabolism a substantial fraction of 
the intramitochondrial NAD
+
 content is gradually reduced. Since only the reduced form, 
NADH is fluorescent, a raise in [NADH]m is considered as a direct indicator of ischemia. 
In this set of experiments NADH was excited at 360nm, while the native cellular 
fluorescence was monitored at 450nm. The relative magnitude of the momentary 
fluorescent shift compared to the maximal raise achieved following the application of 
10mM NaCN has been used to characterize the level of ischemia. Therefore, 
cardiomyocytes were stimulated at 1 Hz and the simulated ischemia/reperfusion protocol 
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(i.e. 3-5 min normoxic control, 20 min simulated ischemia and 10 min reperfusion – see 
details below) was used. At the end of the protocol the cells were exposed to 10 mM 
cyanide, which quickly induced maximal NAD
+ 
reduction. During these measurements 
pO2 levels were repetitively determined using a blood gas analyzer (ABL 505, Radiometer, 
Denmark) in 50 µl samples collected from the central area of the chamber. 
 
2.4. Measuring [Ca
2+
]i transients in single ventricular cardiomyocytes 
 
Fluorescence measurements were performed on the stage of an Olympus IX 71 
inverted fluorescence microscope. [Ca
2+
]i transients were monitored using a Ca
2+
-sensitive 
fluorescent dye, Fluo 4. Isolated cardiomyocytes were loaded with 6 µM Fluo 4-AM (AM 
is the membrane permeable acetoxymethyl ester conjugated form of the dye) for 15 
minutes at room temperature in dark. The dye was excited at 480 nm and the emitted 
fluorescence was detected at 535 nm. Loaded cells were mounted in a low volume imaging 
chamber (RC47FSLP, Warner Instruments) and for steady-state [Ca
2+
]i measurements 
myocytes were stimulated at a constant frequency of 1 Hz through a pair of platinum 
electrodes by an electronic stimulator (Experimetria Ltd, Hungary). While the cells 
superfused with normal (during control and reperfusion periods) or “simulated ischemic” 
Tyrode solution. Optical signals were sampled at 1 kHz and recorded by a photon counting 
photomultiplier module (Hamamatsu, model H7828). Data acquisition and analysis were 
performed using a CAIRN Optoscan System. Alterations in [Ca
2+
]i were characterized by 
the corresponding changes in background corrected fluorescence normalized to the control 
state (F/F0).  Amplitudes of the [Ca
2+
]i transients were calculated as differences between 
systolic and diastolic values. Diastolic [Ca
2+
]i ([Ca
2+
]iD) levels were determined 
immediately before the onset of the stimulus. Systolic [Ca
2+
]i was determined at the peak of 
the corresponding transient. [Ca
2+
]i changes were expressed as fluorescence measured over 
basal unstimulated fluorescence (F/F0). Background fluorescence levels were recorded for 
a few times during each experiment and were used to correct raw fluorescence data. 
2.5. Monitoring of single cell action potentials 
 
Single cell APs were recorded using conventional sharp microelectrodes. Selected 
cardiomyocytes were impaled with high-resistance (20-40 MΏ) electrodes filled with        
3M KCl. APs were recorded with an Axoclamp 900A amplifier (Axon Instruments) and 
were analyzed using the Clampfit 10.0 software (Molecular Devices Corporation). Action 
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potential parameters, like amplitude, plateau level, duration (both APD25 and APD90) and 
triangulation (APD90-APD25) of the AP, and the resting membrane potential were 
determined. 
2.6. Eperimental protocols 
2.6.1. Late Na
+
 current (INaL) protocol 
 
The cardiomyocytes were loaded with Fluo 4-AM at room temperature. ATX-II (2 nM) 
[33.] has been used in [Ca
2+
]i transient measurements. The effect of upregulating INaL using 
ATX-II, which is known to increase substantially the Na
+
 influx due to lengthening of the 
inactivation of INaL. Application of 2 nM ATX-II significantly increased the amplitude of 
the [Ca
2+
]i transient. In each experiment ORM-10103 has been used in a concentration of 
10 µM for inhibition of the exchanger [34.].  
2.6.2. Ischemic experimental approach 
4 principal sets of experiments were performed: cell viability measurements, 
NADH measurements, [Ca
2+
]i transient measurements and AP measurements.  
1) Cell viability measurements: Two subsets of experiments were performed. The 
ischemia/reperfusion protocols were identical to the corresponding subsets of the AP 
measurements (native, untreated and ORM-10103 treated cardiomyocytes). Since in 
normoxic conditions cell survival was usually close to 100% for at least an hour, no 
separate time control (TC) measurements were performed.  
2) [Ca
2+
]i transient measurements. These measurements were carried out in 
cardiomyocytes loaded with Fluo 4-AM.  Five groups of experiments were performed. The 
first group was used for time control; no ischemia/reperfusion (I/R) cycle was applied. In 
the second one (untreated) cells were subjected to a full cycle of ischemia/reperfusion. In 
the third one (ORM-10103) cells were pretreated with 10 µM ORM-10103 at the end of the 
control period but prior to the ischemia/reperfusion cycle. The fourth and fifth groups were 
similar to the second and third ones, with the exception that in order to substantially 
increase the driving force for reverse mode NCX activity these solutions also contained the 
Na
+
/K
+
-ATP-ase (NKA) inhibitor strophantidine (1 µM). 
3) AP measurements: Three groups of experiments were performed. The protocols were 
identical to the corresponding groups of the [Ca
2+
]i transient measurements (i.e. untreated, 
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ORM-10103 treated and time control), but these measurements were carried out using 
unloaded cardiomyocytes. 
4) NADH measurements. Since NADH is inherently fluorescent, no cells in this group had 
to be loaded with external dye. Cardiomyocytes in the first subgroup were utilized as time 
control and were superfused with oxygenated Tyrode solution throughout the experiment; 
no simulated ischemia was introduced. The second subgroup of cells was subjected to a 
full cycle of ischemia/reperfusion. 
2.7. Introducing simulated ischemia 
 
We introduced simulated ischemia by applying an ischemic solution that mimic the 
different aspects of the ischemia:  low pH, low pO2, high K
+
, glucose free, high lactate 
perfusion solution (composition (in mM): 123 NaCl, 6 NaHCO3, 0.9 NaH2PO4, 8 KCl, 0.5 
MgSO4, 2.5 CaCl2 and 20 lactate) [35]. The cells were first perfused with normal Tyrode 
solution (normoxia: 3 min), then with simulated ischemic solution (ischemia: 20 min), and 
finally again with normal Tyrode solution (reperfusion: 10 min). During the ischemic 
period an oxygen-free gas combination (95% N2 + 5% CO2) was layered over the solution. 
Each cell was exposed to the ischemia/reperfusion cycle only once. The oxygen level in 
the ischemic solution was decreased to a very low level by heavily gassing the solution 
with the anoxic gas mixture. The pO2 level in the solution was periodically checked using a 
clinical blood gas analyzer (Radiometer ABL 505). The pO2 level was approximately 180 
mmHg in normal Tyrode. This rapidly declined to about 32 mmHg (determined in the 
chamber) in the ischemic solution, which represents a reasonably high level of hypoxia.  
2.8. Variabilities of APD90 ,APD25 and the [Ca
2+
]i  transient  
The beat-to-beat variability of APD90, APD25, and CaT amplitude were calculated 
by the analysis of 50 consecutive action potentials or [Ca
2+
]i transients from the steady-
state section of the experiment, via using the following formulas:   
BVR(ADP90) = Σ (APD90;i+1-APD90;i)/(nbeatsx√2) 
BVR(ADP25) = Σ (APD25;i+1-APD25;i)/(nbeatsx√2) 
Since the uncorrected CaT amplitude largely depends on nonspecific variables (cell size, 
dye concentration and leakage) and this dependence would also be reflected in the 
variabilities, the simple formula used to calculate short term APD variabilities may not be 
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suitable to properly characterize CaT variabilities. Therefore, we normalized the raw 
variability data to the mean CaT amplitude (CaTTC), calculated from the corresponding 
time control experiments, as follows: 
BVR(CaT) = Σ (CaT amplitude;i+1- CaT amplitude;i)/((nbeatsx√2) x mean CaTTC amplitude) 
2.9. Drugs 
All materials were purchased from Sigma (St. Louis, Mo, USA) except for Fluo 4-
AM (Life Technologies). ORM-10103 was a gift from Orion Pharma (Espoo, Finland). 
The chemical structure of ORM-10103 [5-nitro-2-(2-phenylchroman-6-yloxy) 
pyridine] [34]:  
 
2.10. Data processing and statistics 
Individual cardiomyocytes - even if selected from the same isolation - show great 
variability in size and volume. Consequently, at the end of the loading process their 
fluorescent dye content - even at identical [Ca
2+
]i - showed significant variations and this 
variability was fully reflected by the magnitude of the optical signals. Therefore, to avoid 
abnormally high standard deviations caused solely by the heterogeneity of the dye content, 
fluorescence values were normalized to the control period.  
In contrast to the “survival” data shown in Fig. 8, all single cell data presented in 
Fig.s 5-15 were obtained from living cardiomyocytes, surviving the ischemia/reperfusion 
protocol. Incomplete single cell measurements were discarded from data analysis. All 
values presented are arithmetic means ± S.E.M. All data were analyzed using Students t 
test for paired or unpaired data, as relevant. Differences were considered significant when 
P was less than 0.05.  
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3. RESULTS 
3.1. The physiological effect of selective NCX inhibition on the [Ca
2+
]i transient 
 
Cardiomyocytes were loaded with a Ca
2+
-sensitive fluorescent dye, Fluo 4-AM. In 
time control measurements only a small, gradient decrease in the magnitude and baseline 
of the transient could be observed (Fig. 5A). This gradual decrease is predominantly a 
consequence of dye leakage/extrusion from the cell. Interestingly, in normoxic conditions 
the application of 10 µM ORM-10103 had no apparent effect on the magnitude or kinetics 
of the transient (Fig. 5B).  For selective inhibition of the exchanger, ORM-10103 has been 
used in 10 µM dose. At this dose no apparent effect of the inhibitor on further ion 
transporters (except a small inhibition of IKr) could be observed [34]. In a predominant 
number of cardiomyocytes application of 10 µM ORM-10103 during normoxia did not 
cause apparent changes in the magnitude, shape and decay kinetics of the transient. 
 
 
Fig.5.: Representative traces from the CaT measurements and the effect of 10µM ORM-
10103 on the [Ca
2+
]i transient. Cardiomyocytes were loaded with a Ca
2+
-sensitive 
fluorescent dye, Fluo 4-AM. In a predominant number of cardiomyocytes application of 10 
µM ORM-10103 during normoxia did not cause apparent changes in the magnitude, shape 
and decay kinetics of the transient (B). 
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3.2. Effect of selective NCX inhibition on the INaL induced increase in [Ca
2+
]i transient  
  
INaL was activated by 2 nM ATX-II which is known to increase substantially the Na
+
 influx 
due to lengthening of the inactivation of INaL. Application of 2 nM ATX-II significantly 
enhanced the magnitude of the [Ca
2+
]i transient, but this increase was diminished by 
subsequent application of 10 µM ORM10103 (Fig.6A). In contrast, when 10 µM 
ORM10103 was applied as a pretreatment, the secondary administration of ATX-II failed 
to enhance the [Ca
2+
]i transient (Fig.6B). Statistical significances were verified by repeated 
measure ANOVA. 
 
A
B
 
 
Fig.6.:  The efficacy of NCX inhibition against the INaL activation induced [Ca
2+
]i load.     
2 nM ATX-II significantly enhanced the amplitude of the [Ca
2+
]i transient (A). In contrast, 
when 10 µM ORM-10103 was applied first, the ATX-II induced enhencement of the [Ca2+]i 
transient was reverted by ORM10103 (B). Columns and bars represent means ± SEM 
values, asterisks denote significant differences from control (P<0.05). While # from the 
ATX-II treated group AU represents arbitrary units. 
 
3.3. ORM-10103 decreased the spontaneous diastolic Ca
2+
 releases evoked by Na
+
/K
+
 
pump inhibition 
 We hypothesized that ATX-II induced EADs are caused by Ca
2+
 release from SR 
(which also causes DADs), rather than by reactivation of the L-type Ca
2+
 current during 
prolonged AP (Fig.7). The pacing frequency was set to 1 Hz. During NKA inhibition via 1 
µM strophantidine resulted in significantly enhanced [Ca2+]i transient (A). Pretreatment 
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with 10 µM ORM10103 markedly reduced the effect of the subsequently applied 
strophantidine (B, C).  
 
 
 
 
Fig.7.: Antiarrhythmic efficacy of ORM-10103. Inhibition of the Na
+
/K
+
 pump with 1 µM 
strophantidine resulted in significantly enhanced [Ca
2+
]i transient (A). This enhancement 
could be significantly eliminated if the cells were pretreated with 10 µM ORM-10103 (B). 
In the presence of strophantidine, 2 Hz electrical stimulation caused spontaneous diastolic 
Ca
2+
 releases, which were largely diminished by 10µM ORM-10103 (D). In the case of 
panels (C) and (E), asterisks indicate significant differences from the strophantidine 
treated group. 
This 1 Hz period was than followed by the period of 2 Hz stimulation and a third 
period with stopped stimulation. Since during the 2 Hz period a substantial number of large 
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diastolic releases could be observed, it seems feasible that under these experimental 
conditions a substantial [Ca
2+
]i overload was generated. In the absence of strophantidine 
(control) spontaneous diastolic Ca
2+
 release was not observed following a short period of 
rapid (2 Hz) pacing (D, upper trace). In contrast, rapid pacing induced multiple 
arrhythmogenic Ca
2+
 release events (presumably resulting in DADs) in the presence of 1 
µM strophantidine (D, middle trace). Following 10 µM ORM10103 pretreatment the same 
strophantidine challenge was much less effective to evoke spontaneous Ca
2+
 release (D, 
lower trace and panel E). In panel B the statistical significance level was verified by 
repeated measures ANOVA. 
 
3.4. Effect of selective NCX inhibition on cardiomyocyte viability under ischemic 
conditions 
The results obtained from the “survival” experiments are summarized in Fig. 8. 
Representative microscope fields from a pair of experiments performed on untreated and 
ORM-10103 treated cardiomyocytes are shown in panels (A) and (B), respectively. Instead 
of using vital dyes, we followed a similarly effective classification, based simply on the 
shape and visibility of the striation of the cell [30]. This form of classification may also 
have some benefits since with proper experience one is able to reliably dissect crippled, 
dying cardiomyocytes from safely surviving cells. For survival analysis regions of interest 
(ROIs, white circles) containing ~20 predominantly intact, contracting cardiomyocytes 
were selected at the beginning of the normoxic period (left panels). Based on their 
morphological characteristics cells in the ROI were classified into two groups: Class A: 
elongated cells with intact border and clearly visible striation. Class B: dead cells, or cells 
on the verge of death with no visible striation and typically in full contracture. At the end 
of the ischemic period most cardiomyocytes in both ROIs seem to be principally intact 
(mid panels). At the end of the reperfusion period, however, a substantial number of the 
cells was in contracture (right panels). This is especially true for the untreated group. 
Mean values, determined for both groups in the last minute of the control 
(normoxic), ischemia and reperfusion periods, are summarized in panel (C). The 
distribution of cells in the normoxic state was close to identical in both groups, and the 
majority of these cells were intact (78% and 81% in the untreated and ORM-10103 treated 
groups, respectively). As noted above, ischemia by itself apparently did not influence cell 
distribution in either group. In contrast, reperfusion had a detrimental effect on the 
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untreated group: 71% (112 out of 156) of the cells intact at the end of ischemia died during 
reperfusion. Application of 10 µM ORM-10103 had a clearly protective effect on cell 
viability; significantly less, only 47% (76 out of 161) of the ORM-treated cells died by the 
end of the reperfusion period.   
 
Fig.8.: The effect of 10 µM ORM-10103 on cardiomyocyte viability. Cardiomyocytes were 
classified by their shape: Class A intact border and clearly striation, not significantly 
shortened; Class B dead cells in contracture. Representative microscope fields from 1-1 
experiment performed on untreated (A) and ORM-10103 treated (B) cardiomyocytes The 
mean values are provided on panel (C). The asterisks indicate significant (P<0.05) 
difference between untreated and ORM-treated values (n=10). 
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3.5. Validation of intracellular ischemia by monitoring NADH levels  
 
When the cells were not exposed to ischemia (time control group) only a limited, 
gradual decrease in cellular fluorescence, most likely a consequence of nonspecific 
changes (bleaching), could be observed (black circles). In contrast, in cells exposed to the 
ischemia/reperfusion protocol cellular fluorescence increased significantly during the 
ischemic period (grey circles). When switching perfusion solutions ~30 s was necessary 
for the new perfusate to reach the chamber, and about further ~1 min to mix and decrease 
the oxygen level in the chamber low enough to induce anaerobic transition. Ischemia-
induced NADH shifts were calculated by correcting raw fluorescence values for 
nonspecific changes. The onset and relative depth of intracellular ischemia were verified 
by monitoring ischemia induced shifts in inherent fluorescence of dye-unloaded (native) 
cardiomyocytes and comparing those to nonspecific, time dependent fluorescence shifts 
developed in nonischemic cells. In order to estimate the depth of intracellular ischemia 
NaCN – often used to induce close to maximal short term reduction in NAD+ - was applied 
immediately following the reperfusion period. The results of the NADH fluorescence 
measurements are shown in (Fig.9). 
 
Fig.9.: Effect of simulated ischemia/reperfusion on NADH levels in isolated 
cardiomyocytes. NADH was excited at 360 nm, native cellular fluorescence has been 
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recorded at 450 nm in untreated, unloaded cardiomyocytes (grey circles). Nonspecific 
shifts in fluorescence, caused by NADH bleaching, were estimated from normoxic time 
control measurements (black circles). At the end of both protocols 10mM sodium-cyanate 
(NaCN) was applied to induce maximal NADH reduction (squares). 
I/R=ischemia/reperfusion, TC= time control. Asterisks indicate significant (P<0.05) 
difference between individual ischemic and time control values (n=6). 
 
In the early phase of ischemia a steep increase in [NADH] could be observed (8.4 ± 
0.4%; n = 6). During the ischemic cycle the level of the corrected fluorescence increase 
was varying, most probably reflecting the minor variations in oxygen levels inside the 
chamber. During reperfusion [NADH] gradually returned to control level, even a minimal, 
insignificant undershoot could be observed. Compared to simulated ischemia, the 
application of cyanate induced significantly larger NAD
+
 reduction (ischemic and time 
control cells: 12.2 ± 2.8% and 15.1 ± 1.9%, respectively, n = 4). While the pO2 level in the 
chamber was sufficiently high during normoxia (181.7 ± 7.5 mmHg, n = 25) under 
ischemic perfusion it was always lower than 40 mmHg (32.9 ± 1.6 mmHg, n = 25). 
3.6. The effect of selective NCX inhibition on the [Ca
2+
]i transient during simulated 
ischemia 
During simulated ischemia in both strophantidine untreated (Fig.10A) and treated 
(Fig.11A) cells significant changes in the magnitude and kinetics of the CaT could be 
observed. Ischemia/reperfusion induced changes in characteristic parameters of the CaT in 
strophantidine-untreated cells are summarized in the panels A-E of Figure 10. Significant 
changes in the amplitude of the CaT in untreated compared to time control cells could only 
be observed during the early phase of ischemia (0.836 ± 0.03 vs. 0.979 ± 0.02; n=14) (B). 
In contrast, 10 µM ORM-10103 caused a steady, gradual decrease in the amplitude of the 
CaT (0.76 ± 0.06 vs. 0.38 ± 0.05; n=14), which became significant (compared to ORM-
10103 untreated cells) during reperfusion. In the slope of the transient (C) ischemia 
induced a gradual, significant decrease in untreated cardiomyocytes compared to time 
control (0.55 ± 0.07 vs. 0.54 ± 0.05 n=14) and ORM treatment had no apparent effect on 
this decrease.  
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Fig.10.: Changes in major CaT parameters during simulated ischemia/reperfusion and the 
effect of 10 µM ORM-10103 treatment on these parameters in strophantidine-
untreated cardiomyocytes. (A) Representative raw recordings of CaT in 
cardiomyocites. (B-E) Ischemia/reperfusion induced shifts in major CaT 
variables and the effect of 10 µM ORM-10103 on the (B) magnitude, (C) slope 
and (D) half relaxation time of the transients. Parameter values were obtained in 
the 3
rd
 min (control), 6
th
, 10th, and 15
th
 min (early, mid and late phase of 
ischemia), and 26
th
 and 30
th
 min (early and late phase of reperfusion) of the 
recordings. The changes in [Ca
2+
]iD levels are shown in (E) panel. Fluorescence 
data were analyzed using Students t test for paired or unpaired data, as relevant. 
Hash marks and asterisks indicate significant (P<0.05) difference between 
individual time control vs. untreated and untreated vs. ORM-treated values, 
respectively. 
On the other hand, during reperfusion the slope in the two groups changed in 
opposite direction - recovered in untreated, further decreased in treated cells, the 
differences between the two groups became significant (0.67 ± 0.09 vs. 0.39 ± 0.04; n=14). 
In untreated cells ischemia also caused a significant increase in the half relaxation time 
(RT50) of the CaT, compared to time control (D). In these cells RT50 recovered during 
reperfusion, typically with a moderate undershoot compared to time control. In contrast, 
treatment with ORM-10103 significantly decreased RT50 (0.90 ± 0.03 vs. 0.79 ± 0.03; 
n=14) during late ischemia and reperfusion, compared to untreated cells. The largest 
modulatory effect of ORM-10103 treatment could be observed in [Ca
2+
]iD (E). As 
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expected, ischemia induced a substantial rise in [Ca
2+
]iD, which became significant by the 
2
nd
 min of ischemia. Upon reperfusion [Ca
2+
]iD slowly normalized, however, during its 
early phase (~6 min) it was still significantly higher than in time control cells (1.04 ± 0.03 
vs. 0.92 ± 0.02; n=14). Pretreatment of the cardiomyocytes with 10 µM ORM-10103 
completely eliminated the rise in [Ca
2+
]iD and by the end of the ischemic period it even 
decreased below time control (0.73 ± 0.08 vs. 0.64 ± 0.06; n=14). During reperfusion 
[Ca
2+
]iD in these cells was permanently below control. 
Ischemia/reperfusion induced changes in characteristic parameters of the CaT in 
strophantidine treated cells are summarized in panels A-E of Fig.11. In these cells no 
significant changes in the amplitude of the CaT could be observed during ischemia or 
reperfusion (B). Compared to time control, the slope of the CaT gradually, but significantly 
decreased during both ischemia and reperfusion (C). ORM-10103 failed to influence the 
ischemia induced fall in the slope of the CaT, but significantly limited its further decrease 
during reperfusion (0.55 ± 0.1 vs. 0.21 ± 0.02; n=6). In ORM-10103 untreated cells RT50 
was close to the time control during both ischemia and reperfusion (D). In contrast, the 
application of 10 µM ORM-10103 induced a significant decrease in this parameter during 
reperfusion (1.17 ± 0.11 vs. 0.81 ± 0.06; n=6). The already significant ischemia-induced 
elevation in [Ca
2+
]iD, observed in the untreated myocytes, was further significantly 
augmented in strophantidine treated cells (E) and this marked increase was apparently 
maintained during the entire period of reperfusion. Application of 10 µM ORM-10103 
completely eliminated the huge ischemia induced elevation in [Ca
2+
]iD; indeed, diastolic 
[Ca
2+
]i levels in these cells did not differ significantly from levels measured in normoxic 
cardiomyocytes (0.71 ± 0.06 vs. 0.65± 0.06; n=6). 
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Fig.11.: Changes in major CaT parameters during simulated ischemia/reperfusion and the 
effect of 10 µM ORM-10103 in strophantidine-treated cardiomyocytes. Representative raw 
recordings of CaT from untreated (upper traces) and ORM-treated (lower traces) cells 
prior to, during and following simulated ischemia. (B-E) Ischemia/reperfusion induced 
shifts in major CaT variables and the effect of 10 µM ORM-10103 on the (B) magnitude, 
(C) slope and (D) half relaxation time of the transients, and (E) [Ca
2+
]iD levels. Data were 
analyzed using Students t test for paired or unpaired data, as relevant revealed that the 
difference between untreated and ORM-treated curves in both experimental settings is 
significant (P<0.05). The asterisks indicate significant (P<0.05) difference between 
individual untreated and ORM-treated values. 
 
The beneficial effect of ORM-10103 treatment during reperfusion became even 
more evident by comparing short term variabilities of the CaT amplitudes. Variabilities 
calculated from all four experimental groups for the normoxic, ischemic and reperfusion 
periods are summarized in Fig.12. Representative Poincare plots, obtained in untreated, 
ORM-10103 treated, strophantidine treated and strophantidine + ORM-10103 treated cells, 
are shown in panels A, B, C and D, respectively. Mean data from untreated and ORM-
10103 treated cells are provided in panel (E). As one can conclude from these diagrams, in 
untreated cells no apparent ischemia/reperfusion induced changes in CaT variabilities 
33 
 
could be observed, while ORM-10103 treatment caused a small, rather insignificant 
decrease in both cases (0,011 ± 0.002 vs. 0.010 ± 0.001 and 0,012 ± 0.003 vs. 0.010 ± 
0.001; n=6, during ischemia and reperfusion, respectively). In contrast, as shown in panel 
(F), during ischemia strophantidine significantly enhanced the short term variability (0.113 
± 0.037 vs. 0.037 ± 0.016; n=6) which was even further augmented during reperfusion 
(0,272,± 0,055. vs. 0,018 ± 0,009; n=6). This large elevation was, again, fully eliminated 
by the application of 10 µM ORM-10103.  
 
Fig.12.: The effect of 10µM ORM-10103 on the variability of the [Ca2+]i transient 
amplitude. Representative examples are presented in panels (A-D). Variabilities for 
strophantidine-untreated and treated cardiomyocytes are summarized in panels (E) and 
(F), respectively. While no significant differences could be found in the absence of 
strophantidin, in the treated group ischemia and reperfusion caused large, significant 
increase in variability, which was fully prevented by ORM-10103 treatment. The asterisk 
indicates significant (P<0.05) difference between individual untreated and ORM-treated 
values 
3.7. Effect of selective NCX inhibition on AP parameters 
 
Representative AP waveforms are shown in Fig.13. During normoxia 10 µM ORM-
10103 evoked moderate APD shortening without substantially modulating either its 
amplitude or the resting membrane potential (A). During simulated ischemia, however, 
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significant changes in the shape and kinetics of the APs developed and the resting 
membrane potential was depolarized (middle trace in panel B). Both parameters were 
apparently normalized during reperfusion (right trace in panel B). The AP shortening effect 
of 10 µM ORM-10103 observed in normoxic cells was even more evident during both 
ischemia and reperfusion (panel C); however, no additional ORM-10103 induced shifts in 
AP could be observed. Indeed, the ORM-treatment failed to substantially reduce the 
ischemia induced depolarization of the resting membrane potential. 
 
Fig.13.: Representative traces from the action potential measurements. AP measurements 
were performed in native (dye-unloaded) cells. The effect of 10 µM ORM-10103 on 
normoxic cardiomyocytes (A). The effect of the simulated ischemia/reperfusion protocol on 
action potentials recorded from ORM-10103-untreated (B) and treated (C) 
cardiomyocytes, respectively.  
Ischemia/reperfusion induced alterations in the characteristic parameters of the AP 
in untreated and ORM-10103 treated cardiomyocytes are summarized in Fig.14. Compared 
to normoxic cells, ischemia induced a significant reduction in the amplitude, a substantial, 
but not significant decrease in the plateau level of the AP (A, B), and the resting membrane 
potential became significantly depolarized (C). These parameters were practically restored 
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during reperfusion. ORM-10103 had no apparent effect on the magnitude of the ischemia 
induced shifts, neither on the recovery of these variables. 
 
Fig.14.: Changes in major AP parameters during simulated ischemia/reperfusion 
and the effect of 10µM ORM-1010. Parameter values were obtained in the 3rd min 
(control), 6
th
, 10
th
 and 15
th
 min (early, mid and late phase of ischemia), and 26
th
 and 30
th
 
min (early and late phase of reperfusion) of the measurements: (A) amplitude; (B) plateau 
level; (C) resting membrane potential; (D) APD25; (E) APD90; and (F) triangulation. All 
data analyzed using Students t test for paired or unpaired data, as relevant. Hash marks 
and asterisks indicate significant (P<0.05) difference between individual time control vs. 
untreated and untreated vs. ORM-treated values, respectively. 
 
In order to characterize major changes in AP kinetics APD25 (D) and APD90 (E) 
were determined and from these variables AP triangulation was calculated (F). Ischemia 
induced a moderate decrease in APD25 which was normalized during reperfusion. 
Compared to the untreated cells substantially larger decrease in APD25 could be observed 
in ORM-10103 treated cardiomyocytes, became significant in the late phase of ischemia 
and did not recover during reperfusion (0.90 ± 0.09 vs. 0.66 ± 0.09; n=9). Qualitatively 
similar, but augmented ischemia induced shortening could be observed in APD90, however, 
the differences between the two groups were not significant during either ischemia or 
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reperfusion. Compared to the time control cells, ischemia induced a large, significant 
decrease in AP triangulation in both groups, but again, the differences between the 
untreated and ORM-10103 treated groups were not significant (0.61 ± 0.07 vs. 0.76 ± 0.17; 
n=9). 
Results of these calculations of short term variabilities in APD90 and APD25 are 
summarized in Fig.15. Representative Poincare plots taken from untreated and ORM-
10103 treated cardiomyocytes are presented in panels (A-D). The average values obtained 
in the APD90 and APD25 groups are shown in panels (E) and (F), respectively. Under 
normoxic conditions APD variabilities were similar in both groups. Ischemia induced 
moderate, but insignificant decrease in APD90 variabilities in the untreated group, while 
there was no apparent change in the ORM-10103 treated group. In contrast, APD25 
variabilities failed to change in the control group, but showed a tendency to decrease 
following ORM-10103 treatment. During reperfusion the only significant change was an 
elevation in APD90 variabilities determined in the untreated group. ORM-10103 treatment 
eliminated this increase (5.37 ± 0.96 vs. 3.47 ± 0.69 ms; n=9). 
 
Fig.15.: The effect of 10 µM ORM-10103 on APD90 and APD25 variabilities. 
Representative examples for variabilities in APD90 and APD25 in untreated and ORM-
treated groups are presented in panels (A-B) and (C-D), respectively. Summarized data 
are shown in panels (E) and (F). The asterisks indicate significant (P<0.05) difference 
between untreated and ORM-treated values 
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4. Discussion 
 
The possible antiarrhythmic effect of NCX inhibition can be attributed to its 
important role to prevent the INaL-mediated and ischemia/reperfusion induced [Ca
2+
]i 
overload. In both pathological conditions partial NCX inhibition may restore the balance in 
intracellular Ca
2+
 handling, resulting in decreased propensity for arrhythmias. Since the 
cardiac Na
+
/Ca
2+
 exchanger has a crucial role in maintaining [Ca
2+
]i homeostasis, any 
abnormal shift in its transport rate may significantly contribute to alteration of the 
contractile function and electric activity of the heart. In our experiments the effects of 
selective INCX inhibition on [Ca
2+
]i homeostasis have been evaluated under arrhythmogenic 
conditions. 
Enhanced reverse mode activity may induce [Ca
2+
]i overload, while its enhanced 
forward mode transport leads to gradual [Ca
2+
]i loss. [36-38]. While a number of previous 
studies provided important information on the consequences of NCX inhibition in healthy 
and diseased hearts, interpretation of these results was hampered by the fact, that the 
applied inhibitors were not selective [29;40]. In this respect, our results allow new insight 
into the physiological and pathophysiological role of NCX, since we used ORM-10103, a 
new NCX inhibitor with excellent specificity and selectivity [34] during Na
+
 induced 
[Ca
2+
]i load and during simulated ischemia/reperfusion in isolated canine ventricular 
cardiomyocytes [40]. The most important effects of ORM-10103 were studied on CaT and 
AP, parameters relevant in terms of arrhythmia development. Application of 10 µM ORM-
10103 had a clearly protective effect on cell viability because numerous of ORM-untreated 
cells died by the end of the reperfusion period. Moreover ischemia induced a substantial 
rise in [Ca
2+
]iD, and the application of 10 µM ORM-10103 completely eliminated this rise 
in [Ca
2+
]iD. Furthermore, during ischemia/reperfusion the short term variability of the CaT 
and AP - a well known arrhythmia marker – became significantly enhanced in 
strophantidine treated cells, and this large increase was fully eliminated by the application 
of 10 µM ORM-10103.  
4.1. Selective NCX inhibition does not influence CaT kinetics under physiological 
conditions 
In a predominant number of cardiomyocytes applications of NCX inhibition by      
10 µM ORM-10103 during physiological conditions did not cause apparent changes in the 
magnitude, shape and decay kinetics of the CaT. Under physiological conditions we did 
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not find apparent effect on CaT parameters in the present of NCX inhibition by ORM-
10103 (Fig.5). These results are in line with our previous work [41-42]. The background of 
this effect is complex.  As we can find it in the literature, markedly different results were 
obtained in small species, where NCX inhibition increased the magnitude of [Ca
2+
]i 
transients. This may be due to the short action potential duration in contrast to dogs and 
humans, where the action potential duration is longer. NCX spends relatively longer time 
in its forward mode during the AP in small species (rat) than in larger animals (dog), which 
may lead to increased [Ca
2+
]i transient when NCX is blocked [43-44]. This is the possible 
reason why in our canine myocytes ORM-10103 induced changes in CaT was failed. 
4.2. The effect of selective NCX inhibition against INaL induced [Ca
2+
]i rise on the [Ca
2+
]i 
parameters 
The selective NCX inhibitor ORM-10103 effectively reduced the increased [Ca
2+
]i 
and prevented the INaL-mediated rise in [Ca
2+
]i. The ATX-II induced INa increase leads to 
net gain in [Na
+
]i, shifting subsequently the reversal potential of the NCX in ventricular 
cardiomyocytes. If we added ATX-II before the NCX inhibitor, the increased intracellular 
Na
+
 activated the reverse NCX, leading to raised CaTs. Application of an INCX inhibitor 
reduced the enhanced reverse INCX and limited further Ca
2+
 influx. The INaL activation 
caused increase in the [Ca
2+
]i, which was prevented following the selective NCX blockade. 
This secondary increase in revINCX was fully abolished by pretreatment with 10 µM ORM-
10103. This clearly indicates the pathogenetic role of reverse NCX in the INaL -induced 
[Ca
2+
]i overload and arrhythmia. Thus, these data support important role in cardiac 
arrhythmogenesis of the INaL activation and may suggest the beneficial antiarrhythmic 
effects of NCX inhibition (Fig.6-7).    
According to our previous results we would like to examine, whether the NCX 
blocker ORM-10103 is able to prevent [Ca
2+
]i overload under conditions of simulated 
ischemia/reperfusion injury. 
4.3. Selective NCX inhibition increased the cell survival during ischemia/reperfusion  
 
A most direct way to test the efficacy of the selective NCX blockade in protecting 
cardiomyocytes against ischemia/reperfusion injuries is to compare cell survival between 
untreated and treated groups (Fig. 1). The results of these experiments are straightforward 
and seem to support the hypothesis that partial, selective NCX inhibition by ORM-10103 
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may effectively protect the cardiomyocytes from severe ischemia/reperfusion induced 
injuries. This protection is most probably a direct consequence of the NCX inhibitory 
effect on the buildup of ischemia-induced [Ca
2+
]i  overload leading to contracture and 
elevated [Ca
2+
]iD, which may severely compromise mitochondrial function [45]. A further 
contribution of ORM-10103 to cardiomyocyte survival may be its significant stabilizing 
effect on the CaT and APD by inhibiting the ischemic increase in their variabilities [37]. 
4.4. Measurement of the severity of intracellular ischemia  
 
Sustained ischemia is characterized by modified and deprived energy metabolism. 
Oxidative metabolism is blocked, while glycolysis is enhanced [46]. As a consequence of 
the anaerobic shift, the mitochondrial NAD
+
 content is reduced. Increased NADH level is 
reflected by the increased native fluorescence of the cells at 450 nm.  Close to maximal 
NADH levels can be reached by the application of cyanate (CN
-
). The relative magnitude 
of the fluorescence-increase induced by simulated ischemia was compared to the rise 
achieved by the application of 10mM NaCN. This relative increase was used to 
characterize the level of ischemia. 
The fluorescence increase observed in our experiments during the simulated 
ischemia protocol was substantially less than the level reached in the presence of cyanate 
(Fig. 9). Consequently, our protocol could induce only partial ischemia, i.e. the oxidative 
metabolism was severely compromised [21] but not fully abolished. This is not surprising, 
since the oxygen level in the imaging chamber was rather low, but definitely not zeros 
(32.9 ± 1.6 mmHg). Therefore, the simple simulated ischemia protocol is probably more 
suitable to model the lateral, low-flow zone of the infarcted area than the central now-flow 
region. Another important observation was that fluorescence was gradually decreasing 
after reaching an early maximum. This decrease was probably not a consequence of 
NADH bleaching, since the rate of bleaching can satisfactorily be estimated from the time 
control measurements. Indeed, it may arise from two sources. First, pO2 in the chamber 
was probably close to the critical pO2 value for isolated, active cardiomyocytes and even a 
small shift in chamber pO2 may induce substantially larger shift in the NADH 
concentration. Possible reason for the fluorescence decay observed during ischemia is that 
it may also reflect changes in substrate availability. In the moment we have no data to 
settle this issue - both explanations may be possible - they may act even simultaneously. 
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Both [Ca
2+
]i and [Na
+
]i become gradually elevated during ischemia/reperfusion 
[47]. The excessive rise in [Na
+
]i is a consequence of the simultaneous depression of NKA 
and activation of NHE. As a consequence of the increased [Na
+
]i, NCX is shifted towards 
its reverse transport mode. This shift is further facilitated by substantial depolarization of 
the sarcolemma. During reperfusion the already large ischemia-induced elevation of [Ca
2+
]i 
is further increased, partially because of the largely augmented [Na
+
]i caused by the full 
activation of NHE and also due to the facilitating effect of the increased ROS generation 
[48].When combined, these two effects often result in fast and dramatic further increase in 
[Ca
2+
]i leading to extreme overload, reperfusion-induced cellular injury and enhanced 
arrhythmia propensity. [1]. 
 
4.5 The effect of selective NCX inhibition during simulated ischemia/reperfusion on the 
[Ca
2+
]i parameters 
According to our results consequences of [Ca
2+
]i accumulation could be observed in 
untreated cells (Fig.10A-E). Diastolic [Ca
2+
]i significantly increased (Fig.10A), and since 
the amplitude of the transient did not decrease simultaneously (Fig.10B), systolic [Ca
2+
]i 
was also enhanced (not shown). The kinetic parameters of CaT were also altered. The 
slope of the transient decreased, while RT50 increased during ischemia (Fig.10C-D), 
reflecting the relative energy deficit as a consequence of the metabolic transition. The 
background of this effect may be rather complex: ATP depletion reduces SERCA activity 
(leading to decreased Ca
2+
 content of the SR; see the reduced slope and amplitude of the 
CaT), the increased resting membrane potential decreases the drive for the forward, the 
high [Na
+
]i  increases the drive for reverse NCX current [1], the latter facilitates Ca
2+
 
influx leading to elevated [Ca
2+
]i level to be extruded [4;49]. Therefore, we suggest that in 
this experimental model the Ca
2+
i content of the SR is decreased (via reduced SERCA and 
forward NCX activity), the [Ca
2+
]i level is elevated. Upon reperfusion the amplitude and 
slope of the [Ca
2+
]i transient and – although quite slowly – the diastolic [Ca
2+
]i were 
restored [40]. In contrast, RT50 was significantly shortened during reperfusion. The 
acceleration of [Ca
2+
]i transient relaxation in reperfusion may be related to quick recovery 
of normal K
+
 level, and membrane hyperpolarization, which may significantly increase the 
speed and efficacy of forward NCX. Furthermore the recovery of ATP level increases the 
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SERCA activity as well. The reduction of RT50 below the control level during reperfusion 
may reflect some “overshoot” of the [Ca2+]i handling during recovery [20].  
Pretreatment with 10 µM ORM-10103 displayed an important modulatory effect on 
the response of cardiomyocytes to ischemia/reperfusion. The amplitude and slope of the 
CaT were gradually decreased, although these differences became significant during the 
reperfusion period only. The large decrease in the amplitude of the CaT in the ORM-10103 
treated group may support the notion that during ischemia the NCX mediated beat-to-beat 
Ca
2+
 influx has an important role in compensating the reduced SR Ca
2+
 content. More 
importantly, the ischemia induced large increase in diastolic [Ca
2+
]i and the elevation of 
RT50 were completely blocked by ORM-10103 treatment and in this case a significant 
decrease in these parameters could be observed during reperfusion. These results provide 
direct support for the hypothesis that during ischemia/reperfusion the predominant effect of 
ORM-10103 treatment is an effective suppression of the [Na
+
]i accumulation induced 
massive activation of the reverse mode activity of NCX [50]. 
A further support to this conclusion was provided by the results from the 
strophantidine experiments. Application of 1 µM strophantidine blocks the sarcolemmal 
Na
+
/K
+
-ATP-ase effectively, thus facilitating intracellular Na
+
 accumulation, which in 
turn, shifts NCX activity to even more reverse direction. The ischemia induced elevation of 
diastolic [Ca
2+
]i in these cells [39-40] was higher than in cardiomyocytes not treated with 
strophantidine, and in contrast to the untreated cells, it was further increased during 
reperfusion (Fig.11B). However, this effect was completely blocked by 10 µM ORM-
10103. Another similarly important and promising effect of ORM-10103 on cellular [Ca
2+
]i 
handling is summarized in (Fig.12). In strophantidine-untreated cardiomyocytes the 
variability of the CaT amplitude was limited and did not increase significantly during 
ischemia or reperfusion showing maintained control of Ca
2+
 release on transsarcolemmal 
Ca
2+
 fluxes. In these cells ORM-10103 had no apparent effect on variability. In contrast, 
CaT variability in the strophantidine-treated cells was substantially augmented during 
ischemia and especially during reperfusion. This is probably a consequence of the large 
increase in Ca
2+
i level: the steady-state balance between the trigger and feed-back system 
may be disturbed by the elevated [Ca
2+
]i, leading to fluctuations in the beat-to-beat Ca
2+
 
release and instability of Ca-handling [45]. This increase was completely diminished by 
ORM-10103 treatment, which may be related to the reduction of [Ca
2+
]i. Since the largely 
increased CaT variability can be considered as a marker for the increased arrhythmia 
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propensity at the cellular level [51], a reasonable interpretation of these results is that 
ORM-10103 is likely to decrease the incidence of Ca
2+
-dependent cardiac arrhythmias 
induced by ischemia/reperfusion. 
The results of the CaT experiments seem to strongly support the beneficial effects 
of ORM-10103 treatment on the [Ca
2+
]i homeostasis in cardiomyocytes during INaL-
mediated rise in [Ca
2+
]i and an ischemia/reperfusion injury, by practically eliminating the 
[Ca
2+
]i overload together with its detrimental consequences and by largely decreasing the 
arrhythmia propensity of the heart [52-53]. 
 
4.6. Selective NCX inhibition causes only minor changes on AP morphology  
 
Ischemia/reperfusion induced arrhythmias are generated by two major, but not 
independent mechanisms: [Ca
2+
]i overload, and depolarization of the sarcolemma [28]. 
[Ca
2+
]i overload may cause increased Ca
2+
 leakage from the SR, thus substantially 
enhancing the generation of spontaneous diastolic releases (sparks), and Ca
2+
-dependent 
triggered arrhythmias [49]. These stochastic Ca
2+
 releases generate large inward current, 
perhaps via increased forward NCX transport activity, which in turn depolarizes the 
sarcolemma. Therefore, these release events can serve as the trigger for potentially lethal 
ventricular arrhythmias [54].  Elevated [K
+
]o causes considerable membrane depolarization 
reducing the availability and recovery of Na
+
 and Ca
2+
 channels, furthermore the 
depolarization attenuates Ca
2+
 extrusion [48]. Ca
2+
 elevation may generate enhanced Ca
2+
 
efflux through the forward NCX, meanwhile the ATP depletion induced activation of 
IK(ATP) channels carries extra repolarizing current, which may contribute to AP shortening 
during ischemia-reperfusion. The substantial redistribution of ion fluxes both in the 
repolarizing currents, and in the Ca
2+
 fluxes, may contribute the increased short-term 
APD90 variability during reperfusion.  Pretreatment of normoxic (time control) cells with 
10 µM ORM-10103 caused a moderate shortening of the AP (Fig.13A) which may be 
related to the inhibition of forward NCX activity. No further apparent changes were 
observed. Ischemia substantially depolarized the membrane as a consequence of the 
enhanced [K
+
]o (Fig.13B) and eliminated the spike potential, but both parameters were 
restored during reperfusion. ORM-10103 treatment failed to protect the cells against these 
ischemia induced changes (Fig.13C). The only beneficial effect of NCX inhibition on 
ischemia/reperfusion induced shifts in AP parameters was a significant reduction in APD90 
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variability during reperfusion, which may be a consequence of increased stability of Ca
2+
 -
handling following the application of ORM-10103.  
The apparent failure of ORM-10103 to modulate the ischemic AP is even better 
shown in the panels of Fig.14. Ischemia induced changes in AP parameters (i.e. the 
significantly depressed amplitude (A), plateau (B), and marked triangulation (F), as well as 
the depolarized resting potential) were practically uninfluenced by the application of 
ORM-10103. As already mentioned, ischemia induced shortening of the AP (both at 
APD25 and APD90 levels) were even further shortened by ORM-10103 (D-E). The reason 
for this unability of the NCX inhibitor to prevent the protective effects of 
ischemia/reperfusion on the AP may be quite complex. Changes in [Ca
2+
]i  are likely 
important modulators of the membrane potential at any time during the cardiac cycle [49.] 
however, the shape and kinetics of the AP are much more dependent on several other 
parameters, including the inward Na
+ 
and outward K
+
 currents. Neither of these were 
affected directly by ORM-10103. This may be the primary cause for the limited sensitivity 
of the AP to selective NCX blockade. The only apparent beneficial effect of ORM-10103 
on variables of the action potential was a significant reduction in reperfusion-induced rise 
of APD90 variabilities [55]. This may be a consequence of the increased stability of Ca
2+
-
handling and is most probably a consequence of the decreased [Ca
2+
]i overload and 
reduced [Ca
2+
]iD. 
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5. CONCLUSION 
Until recently, the lack of proper NCX inhibitors significantly hampered the efforts 
to answer the question, how selective NCX inhibition would modulate the arrythmogenic 
consequences of severe Ca
2+
 overload, induced by either increased late sodium current or 
ischemia/reperfusion. That is the reason, why the overall conclusion of the present study, 
i.e. that treatment by a highly selective NCX inhibitor, ORM-10103 proved to effectively 
improve the cell viability during ischemia/reperfusion injury, seems to be really important.  
ORM-10103 apparently normalized the stability of the [Ca
2+
]i transient markedly 
weakened during reperfusion and facilitated the post-reperfusion survival of the 
cardiomyocytes. Its beneficial, preventive action against the arrhythmogenic shifts in 
[Ca
2+
]i homeostasis caused by elevated late sodium current or ischemia/reperfusion can 
apparently be a consequence of its limiting effect on [Ca
2+
]i overload and subsequent 
elimination of the ischemia-induced rise in diastolic [Ca
2+
]i. These effects may have 
primarily contributed to the effective inhibition of the [Na
+
]i rise-induced, significantly 
enhanced reverse mode transport activity of the Na
+
/Ca
2+
 exchanger. On the other hand, in 
certain pathological conditions, where the source of arrhythmia is the disturbed AP 
morphology and to lesser extent the [Ca
2+
]i overload, the protective efficacy of ORM-
10103 is rather limited, since it is apparent unable to prevent or significantly decrease these 
arrhythmogenic AP changes. Therefore, it can be stated that selective NCX inhibition 
might best be used to protect the heart against the arrhythmogenic effects of Na
+
 induced 
[Ca
2+
]i overload and the subsequent cell death.  
Selective NCX inhibitors might be the key to find a way to have antiarrhythmic 
effect against the INaL-mediated and ischemia/reperfusion induced [Ca
2+
]i overload and cell 
death.  
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6. LIMITATIONS 
Our studies revealed that inhibition of the NCX by applying inhibitors that does not 
affect the L-type Ca
2+
 current, the major source of Ca
2+
 influx, may protect the cardiac 
myocytes against [Ca
2+
]i overload, preventing the deleterious consequences of the 
sustained high intracellular Ca
2+
. Since [Ca
2+
]i overload has a crucial pathogenetic role in a 
variety of pathophysiological situations, our results support the hypothesis that selective 
NCX inhibition can be beneficial in differerent cardiac diseases.  However, extrapolation 
of our experimental results to the human pathophysiology must be careful. For example, 
the severity of the simulated ischemia in our studies was only mild, thus beneficial effect 
of the NCX inhibition in real situations cannot be granted based solely on our results. 
Therefore, further studies, using more sophisticated experimental approaches, are needed 
to study the therapeutic potential of the NCX inhibition.   
It must be emphasized, that the data provided in Fig.8 differ from data presented in 
Fig.s 5-15. “Survival” experiments were performed on full cell populations (the only 
criterion when selecting the ROI at the beginning of the experiments was to find an area 
with predominantly healthy, contracting cells). Our present data shown in Fig.8 and data in 
the literature [30] clearly demonstrate that a significant fraction of the cardiomyocytes does 
not survive the simulated ischemia protocol and dies during the reperfusion period. Since 
incomplete measurements were discarded from further proccessing, all single cell (NADH, 
CaT, and AP) data presented were obtained from a limited cellular pool – i.e. surviving 
cells.  
Furthermore, during simulated ischemia a 90% N2-10% O2 gas phase was directed 
over the top of the chamber and in the simulated ischemic solution before it arrives to the 
chamber. The O2 value was difficult to set to appropriate level in the chamber. That is the 
reason why this protocol characterization was really difficult.  
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